OPEN ACCESS Freely available online

ISSN: 2167-1052
Advances in Pharmacoepidemiology and Drug Safety

Opinion Article

Overview on Acyclovir uses, Mechanism of Actions and Clinical Applications

San Francisco*

Department of Internal Medicine and Neurology, University of Wright State, Dayton, USA

DESCRIPTION

The immense universe of pharmaceutical advancements, few compounds have revolutionized the treatment of viral infections as profoundly as acyclovir. Acyclovir, classified as a synthetic nucleoside analog, has emerged as a cornerstone in the management of herpesvirus infections. Since its discovery and subsequent introduction to the medical world in the late 1970s, acyclovir has showcased its remarkable efficacy, safety profile, and versatility in targeting a spectrum of herpesvirus infections.

Discovery and mechanism of action

Acyclovir's story begins with its discovery by the eminent pharmacologist Gertrude B. Elion and her collaborator George H. Hitchings at Burroughs Wellcome (now GlaxoSmithKline). The duo's innovative work in the field of rational drug design led to the creation of acyclovir, a compound that would eventually reshape the antiviral landscape. Acyclovir's mechanism of action is rooted in its unique structure and its targeted interference with viral replication.

As a nucleoside analog, acyclovir closely resembles the building blocks of DNA, specifically the nucleoside deoxyguanosine. Upon entering an infected cell, acyclovir undergoes a series of phosphorylation steps by viral and cellular enzymes. The final phosphorylation step, catalyzed by the viral enzyme thymidine kinase, converts acyclovir into its active triphosphate form. This acyclovir triphosphate competes with deoxyguanosine triphosphate during DNA synthesis. When incorporated into a growing DNA strand, acyclovir triphosphate acts as a "chain terminator," preventing further elongation. This selective inhibition primarily affects viral DNA replication, as the viral thymidine kinase preferentially phosphorylates acyclovir over cellular thymidine.

Clinical applications

Acyclovir's therapeutic prowess lies in its remarkable efficacy against a spectrum of herpesvirus infections. These infections encompass a variety of clinical presentations and severity levels, ranging from mild cold sores to life-threatening disseminated infections. The key herpesviruses targeted by acyclovir include Herpes Simplex Virus type 1 (HSV-1), Herpes Simplex Virus type 2 (HSV-2), and Varicella-Zoster Virus (VZV).

Herpes simplex virus: Acyclovir has emerged as the gilded standard for treating herpes simplex infections. Its topical formulation is commonly used to manage oral and genital herpes lesions, offering symptomatic relief and expediting the healing process. In severe cases, such as disseminated or encephalitic herpes, intravenous acyclovir is the treatment of choice.

Varicella-Zoster virus: The effectiveness of acyclovir against varicella-zoster virus has transformed the management of chickenpox (varicella) and shingles (herpes zoster). Administered promptly after the onset of symptoms, acyclovir can mitigate the severity and duration of the rash, as well as reduce the risk of complications such as postherpetic neuralgia.

Prophylaxis and immunocompromised patients: Acyclovir plays a significant role in preventing herpesvirus reactivation in immunocompromised individuals, such as those undergoing organ transplantation or receiving immunosuppressive therapies. Prophylactic acyclovir significantly reduces the risk of viral complications in these vulnerable populations.

Resistance and future implications

While acyclovir has undoubtedly revolutionized herpesvirus management, the emergence of drug-resistant strains warrants careful consideration. Prolonged or suboptimal use of acyclovir can lead to the selection of viral variants with altered thymidine kinase or DNA polymerase, rendering them less susceptible to the drug's effects. This phenomenon highlights the importance of judicious acyclovir use and the need for ongoing research to develop novel antiviral strategies.

The future of acyclovir lies not only in optimizing its use but also in exploring its potential beyond herpesvirus infections. Researchers

Correspondence to: San Francisco, Department of Internal Medicine and Neurology, University of Wright State, Dayton, USA. E-mail: san@francisc

Received: 03-Jul-2023, Manuscript No. PDS-23-22752; **Editor assigned:** 06-Jul-2023, Pre QC No. PDS-23-22752 (PQ); **Reviewed:** 20-Jul-2023, QC No. PDS-23-22752; **Revised:** 27-Jul-2023, Manuscript No PDS-23-22752 (R); **Published:** 04-Aug-2023, DOI: 10.35248/2167-1052.23.12.322

Citation: Francisco S (2023) Overview on Acyclovir uses, Mechanism of Actions and Clinical Applications. Adv Pharmacoepidemiol Drug Saf. 12:322.

are investigating its efficacy against other viruses, such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV), which belong to the herpesvirus family. Additionally, acyclovir's mode of action, specifically its interference with DNA synthesis, has inspired investigations into its potential role in combating certain cancers that rely heavily on uncontrolled DNA replication.

REFERENCES

1. De Weerd NA, Nguyen T. The interferons and their receptors—distribution and regulation. Immunol Cell Biol. 2012;90(5):483-491.
2. Domańska-Blicharz K, Woźniakowski G, Konopka B. Animal coronaviruses in the light of COVID-19. J Vet Res. 2020;64(3):333-345.
3. Domingo JL. What we know and what we need to know about the origin of SARS-CoV-2. Environ Res 2021;200.
4. Fensterl V, Sen GC. Interferons and viral infections. BioFactors. 2009;35(1):14-20.
5. Friedman RM. Clinical uses of interferons. Br J Clin Pharmacol. 2008;65(2):158-162.
6. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135(1):44-53.
7. Geraghty RJ, Capes-Davis A, Davis JM. Guidelines for the use of cell lines in biomedical research. Br J Cancer. 2014;111(6):1021-1046.
8. Gutierrez-Merino J, Isla B, Combes T, Martinez-Estrada F, Maluquer De Motes C. Beneficial bacteria activate type-I interferon production *via* the intracellular cytosolic sensors STING and MAVS. Gut Microbes. 2020;11(4):771-788.
9. Jhuti D, Rawat A, Guo CM, Wilson LA, Mills EJ, Forrest JI. Interferon treatments for SARS-CoV-2: challenges and opportunities. Infect Dis Ther. 2022;11(3):953-972.
10. Kaur G, Dufour JM. Cell lines: valuable tools or useless artifacts. Spermatogenesis. 2012;2(1):1-5.